Article Sidebar
Article Details
The author(s) retain copyright on work published by AOSIS unless specified otherwise.
Licensing and publishing rights
Author(s) of work published by AOSIS are required to grant AOSIS the unlimited rights to publish the definitive work in any format, language and medium, for any lawful purpose. AOSIS requires journal authors to publish their work in open access under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence.
Read more here: http://creativecommons.org/licenses/by/4.0/.
The authors retain the non-exclusive right to do anything they wish with the published article(s), provided attribution is given to the applicable journal with details of the original publication, as set out in the official citation of the article published in the journal. The retained right specifically includes the right to post the article on the authors’ or their institution’s websites or in institutional repositories.
Previously published work may have been published under a different licence. We advise the community that if they would like to reuse the work to consult the applicable licence at article level.
Main Article Content
New antiretroviral drugs: What\'s on the horizon in 2005?
Abstract
Despite the present number of available antiretrovirals (ARVs), there continues to be a need for new medications with improved tolerability, and activity against resistant virus. This article will review three groups of ARVs: those available in North America and
Europe but not yet registered in South Africa; new formulations of drugs for which the parent formulations are already available in South Africa; and promising new compounds in early clinical stages of development. Table I shows the year of approval of ARVs available for treatment of HIV-infected individuals, in both the USA and South Africa and Table II summarises the characteristics and rationale for new ARVs.
Southern African Journal of HIV Medicine Vol. 6 (1) 2005: pp. 32-36
